You are here: Industry Insights > Matrix-M

News List

Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine prnasia
August 06, 2021
Novavax, Inc. today announced that the companies have filed regulatory submissions for emergency use authorization of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.
Novavax and European Commission finalise advance purchase agreement for up to 200 million doses of COVID-19 vaccine expresspharma
August 06, 2021
Novavax has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine prnasia
August 05, 2021
Novavax announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.
Novel vaccine 77 percent effective in preventing malaria, finds study europeanpharmaceuticalreview
April 28, 2021
The R21 vaccine candidate, when administered with 50mg of adjuvant, was found to be 77 percent effective in preventing malaria in children over 12 months.
Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement for Novavax’ COVID-19 Vaccine contractpharma
March 10, 2021
New highly scalable line of bioreactors designed to ensure seamless scalability from early process development to commercial manufacturing.
Novavax concludes subject enrolment in Covid-19 vaccine trial pharmaceutical-technology
February 23, 2021
Biotechnology company Novavax has concluded enrolment in its pivotal Phase III PREVENT-19 study of Covid-19 vaccine candidate, NVX-CoV2373, in the US and Mexico.
Novavax announces initiation of PREVENT-19 pivotal Phase 3 efficacy trial of COVID-19 vaccine in the United States and Mexico worldpharmanews
December 29, 2020
Novavax, Inc. announced initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, the Company's COVID-19 vaccine candidate.
AGC Biologics, Novavax Expand Coronavirus Vax Pact contractpharma
August 12, 2020
Expands supply of Matrix-M adjuvant for Novavax’ coronavirus vaccine, NVX-CoV2373, from its facility in Seattle for U.S. supply.
Novavax presents positive data from Phase I COVID-19 vaccine trial europeanpharmaceuticalreview
August 07, 2020
A Phase I trial conducted by Novavax to test NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate, showed it elicited robust antibody responses.